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Abstract
Purpose We aim to evaluate the safety of PGD. We focus on the congenital malformation rate and additionally report on adverse
perinatal outcome.
Methods We collated data from a large group of singletons and multiples born after PGD between 1995 and 2014. Data on
congenital malformation rates in live born children and terminated pregnancies, misdiagnosis rate, birth parameters, perinatal
mortality, and hospital admissions were prospectively collected by questionnaires.
Results Four hundred thirty-nine pregnancies in 381 women resulted in 364 live born children. Nine children (2.5%) had major
malformations. This percentage is consistent with other PGD cohorts and comparable to the prevalence reported by the European
Surveillance of Congenital Anomalies (EUROCAT).We reported one misdiagnosis resulting in a spontaneous abortion of a fetus
with an unbalanced chromosome pattern. 20% of the children were born premature (< 37 weeks) and less than 15% had a low
birth weight. The incidence of hospital admissions is in line with prematurity and low birth weight rate. One child from a twin,
one child from a triplet, and one singleton died at 23, 32, and 37 weeks of gestation respectively.
Conclusions We found no evidence that PGD treatment increases the risk on congenital malformations or adverse perinatal
outcome.
Trial registration number NCT 2 149485
Keywords Preimplantation genetic diagnosis . Perinatal outcome . Congenital malformations . Children . Follow-up
Electronic supplementary material The online version of this article
(https://doi.org/10.1007/s10815-018-1286-2) contains supplementary
material, which is available to authorized users.
* Malou Heijligers
m.heijligers@mumc.nl
1 Department of Clinical Genetics, Maastricht University Medical
Center, Maastricht, The Netherlands
2 School for Oncology and Developmental Biology, GROW,
Maastricht University, Maastricht, The Netherlands
3 Department of Obstetrics and Gynaecology, Maastricht University
Medical Center, Maastricht, The Netherlands
4 Department of Reproductive Medicine, University Medical Center
Utrecht, Utrecht, The Netherlands
5 Department of Genetics, University Medical Center Groningen,
Groningen, The Netherlands
6 Department of Obstetrics and Gynaecology, University Medical
Center Groningen, Groningen, The Netherlands
7 Department of Clinical Epidemiology and Medical Technology
Assessment, Maastricht University Medical Center,
Maastricht, The Netherlands
8 Department of Pediatrics, Maastricht University Medical Center,
Maastricht, The Netherlands
Journal of Assisted Reproduction and Genetics
https://doi.org/10.1007/s10815-018-1286-2
Introduction
Preimplantation genetic diagnosis (PGD) offers couples at
high risk for transmitting a genetic disease to their offspring
an alternative to prenatal diagnosis or may enhance their prob-
ability of an ongoing pregnancy if one of the parents is carrier
of a structural chromosomal abnormality [1]. Couples opting
for PGD have to go through IVF treatment with or without
ICSI to obtain embryos for genetic analysis. Blastomeres or
trophectoderm (TE) cells for diagnosis are procured through
embryo biopsy and analyzed by either polymerase chain reac-
tion (PCR), fluorescence in situ hybridization (FISH), or
array-comparative genomic hybridization (array-CGH) in or-
der to determine a specific genetic defect or a chromosomal
abnormality [2].
It is hypothesized that assisted reproductive technolo-
gies, especially more invasive techniques like ICSI, in-
crease the risk on birth defects [3, 4]. The need for em-
bryo biopsy makes PGD an even more invasive procedure
than IVF(-ICSI) treatment alone. It should also be taken
into account that the majority of the PGD couples have no
history of fertility problems and alternatively could
choose for a natural conception with or without invasive
prenatal testing. Consequently, the safety of PGD is an
issue that needs constant scrutinizing, the more since the
number of pregnancies after PGD is increasing over the
years [5]. Since the first PGD treatment was performed in
the early 1990s [6], clinical studies on PGD pregnancies
and children born after PGD did not report a higher rate
of major congenital malformations when compared to
IVF-ICSI children [7–12]. The results of these studies
raise concerns about adverse perinatal and neonatal out-
come, like prematurity rate, the incidence of low, and very
low birth weight as well as the incidence of perinatal
mortality. However, the reported data are derived from
only one large and three small cohorts which makes col-
lection of more data desirable. Also, these cohorts mostly
contain data on pregnancies and children born after pre-
implantation genetic screening (PGS), and thus include
couples with a history of infertility or advanced maternal
age.
This study presents mostly prospectively collected da-
ta concerning the perinatal outcome of all PGD preg-
nancies in the Netherlands between 1995 and 2014.
PGS pregnancies are not included. In view of earlier
reported concerns and accompanying importance for pa-
tients and health care providers, the aim of this study is
to establish the safety of PGD in the Netherlands and to
contribute to the justification of PGD as a tool in her-
itable disease prevention. We focus on the congenital
malformation rate and additionally report on misdiagno-




The study describes results from 439 PGD pregnancies and
366 newborns, originating from all PGD cycles started be-
tween 1995 and 2014 in the Netherlands. Two hundred and
forty IVF-ICSI treatments were performed in the Maastricht
UniversityMedical Centre+ (MUMC+), 161 in the University
Medical Centre Utrecht (UMCU), 36 in the University
Medical Centre Groningen (UMCG), and two in the
Amsterdam Medical Centre (AMC). The latter three IVF de-
partments are PGD transport centers [13]. All genetic analyses
were performed at the department of Clinical Genetics of the
MUMC+.
PGD procedure
Ovarian downregulation and follicular growth stimulation
protocols were performed according to local protocols, as well
as the procedures for IVF or ICSI, but they resemble the pro-
cedures applied at the MUMC+ [14, 15]. On day three after
oocyte retrieval and fertilization by IVF (only for FISH anal-
ysis) or ICSI one or two blastomeres were removed from
cleavage stage embryos for genetic analysis. A laser was used
to make a hole in the zona pellucida and replaced the use of
acidic Tyrode in the early years of PGD. Blastomeres were
analyzed using PCR in case of monogenetic or mitochondrial
conditions and FISH analysis in case of chromosomal abnor-
malities. Recently, array-CGH (aCGH) has replaced the FISH
technique. Embryos were cultured in individual drops of me-
dium where the development was recorded. On day three or
four after oocyte retrieval, one or two unaffected embryos
were transferred [16]. For PGD-FISH cases, the genetic anal-
ysis only included the chromosomes involved in the translo-
cation. In case of PGD-aCGH, a comprehensive analysis was
performed and only normal/balanced-euploid embryos were
eligible for transfer. A single embryo transfer (SET) policy has
been installed by the Dutch government since 2013, though a
preference for SET had already been developed since 2006
[17].
Study procedure
Data on IVF-ICSI treatments and PGD analyses were collect-
ed from the medical files in either the clinical genetics depart-
ment or the IVF departments of the participating centers. In
the first weeks after the birth of their child, the parents filled in
a comprehensive questionnaire about the pregnancy and the
health of their child. They were asked for consent to gather
medical information about pregnancy, delivery, and the health
of their child. Additional data regarding pregnancy, delivery,
or the newborn were requested from the patient’s
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gynecologist, the observing midwife practice, or the treating
pediatrician, respectively. The collected data included the fol-
lowing: age of both parents at embryo transfer, gravidity, par-
ity, and number of previous IVF/PGD cycles per couple,
whether pregnancy was derived from a fresh or frozen/
thawed embryo, after usage of IVF or ICSI and PCR, FISH,
or array-CGH for analysis, number of blastomeres biopsied,
number of transferred embryos, number of live born children,
gender, singleton or multiple, PGD indication, major and mi-
nor malformations, still births, pregnancy terminations, mis-
diagnosis, pre- and postnatal genetic testing, term at delivery,
birth weight, perinatal mortality, and hospital admissions.
Statistics
SPSS version 22 (IBM SPSS, Chicago, IL) was used for de-
scriptive statistics. The categorical data are presented as pro-
portions. The continuous data are presented as mean and stan-
dard deviation. Further, z-scores were calculated for birth
weight of all singletons by normalizing the weight of each
child using the mean weight with standard deviation of chil-
dren from a reference population with similar maternal parity,
fetal gender, ethnic background, and gestational age
(Foundation for Perinatal Registration in the Netherlands
2013).
Definitions
Congenital malformations are all structural, functional,
and genetic anomalies diagnosed in aborted fetuses, at
birth, or in the neonatal period. Minor anomalies are
those which do not have serious medical, functional,
or cosmetic consequences for the child, according to
the European Surveillance of Congenital Anomalies
[18].
We used the following ICMART definitions [19]: an
ongoing pregnancy is defined as having a pregnancy
duration of more than 12 weeks. A miscarriage is de-
fined as the spontaneous loss of a pregnancy before 20
completed weeks of gestational age. A still birth is de-
fined as death before the complete expulsion or extrac-
tion from its mother, at or after 20 completed weeks of
gestational age. Deliveries before 37 completed weeks
of gestation are defined premature and a child is born
very premature when delivered before 32 weeks of ges-
tational age. Low birth weight is defined as a birth
weight less than 2500 g and very low birth weight as
less than 1500 g. Perinatal mortality denotes fetal or
neonatal death during the second term of the pregnancy
(after 20 weeks), during delivery, or until 7 days after
the date of birth.
Results
The characteristics of the couples, treatments, and children are
shown in Table 1. Fifty-three percent of the pregnancies orig-
inated from the first PGD cycle. ICSI was used for fertilization
in 69% of the procedures. The distribution between either one
or two biopsied blastomeres was equal. Slightly more often
one embryo was transferred.
Four hundred and thirty-nine clinical pregnancies resulted
in 366 children. Two children were lost to follow-up and ex-
cluded from analyses. Thirteen percent of the pregnancies
were multiple pregnancies and 28% of the live born children
were part of a twin or triplet. In 85.5% of the multiple preg-
nancies, two embryos were transferred. There was a decline in
the double embryos transfer rate and the occurrence of multi-
ple pregnancies over time.
The largest proportion of couples (39%) opted for PGD
because of an autosomal dominant (AD) disorder.
Huntington disease (12%), myotonic dystrophy (6%), and he-
reditary breast and ovarian cancer (5%) were the most com-
mon AD conditions. PGD for reciprocal translocations (18%)
was the most requested indication of all and PGD because of a
mitochondrial condition the least (0.9%).
Safety of PGD
Congenital malformation rate
Major malformations were seen in nine of the 364 live born
children (2.5%) (Table 2). Four of these children showed mul-
tiple congenital anomalies (MCA): two had a chromosomal
abnormality (one singleton had trisomy 21 and one of a twin
had trisomy 9 mosaicism), one child presented with an atrial
septum defect grade II, an orofacial cleft , and a
hydronephrosis, and the fourth had an unilateral facial nerve
paresis and microtia. The (genetic) cause in the latter two was
not found. Three children had a single congenital malforma-
tion; a bilateral hydronephrosis, a duodenal web, and a hypo-
spadia, respectively. Isolated congenital heart defects were
reported in two children; one atrial and ventricular septum
defect and one atrial septum defect in combination with a
pulmonary stenosis.
Five children (1.4%) had a minor malformation.
Ultrasound of the neonatal spine in two children with a sacral
dimple showed closed vertebrae. Three children presented
with a congenital herniation: two twin sisters both had an
umbilical hernia and a singleton had an inguinal hernia. The
twin sisters were born very premature at 29 + 3 weeks gesta-
tional age.
An acardiac fetus was detected in a triplet pregnancy and
led to a miscarriage. Three pregnancies were terminated be-
cause the fetuses were diagnosed with an exencephaly, triso-
my 18, and trisomy 21, respectively.
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In six pregnancies, ultrasound abnormalities were reported
which were not confirmed postnatally. Hydronephrosis was
diagnosed four times on ultrasound and one girl was suspected
to have an abdominal cyst. In one pregnancy, the three-vessel
view was suspect for a cardiac anomaly, but postnatal follow-
up showed none (data not further shown).
Misdiagnosis
One misdiagnosis is currently known. Chromosomal analysis
of a fetus with a negative heart beat on ultrasound showed an
unbalanced 47,XX,+der(5)t(X;5)(q13;p14)mat karyotype.
The mother was a 46,X,t(X;5)(q13;p14) carrier. PGD analysis
was done using FISH (Table 2).
Genetic testing, either, pre- or postnatal, was performed in
10% of the pregnancies. In 53% of the cases, the reason for
testing was confirmation of the PGD diagnosis, all were con-
firmed. Other indications were miscarriages, an increased risk
for a trisomic fetus and abnormalities on ultrasound suspect
for congenital malformations in the newborn.
Birth parameters
Eighty percent of the children were born at term. Eight chil-
dren (2.2%) were born very premature; all of the latter were
from twin pregnancies (Table 3).
The mean birth weight was 3450 g (± 533) for singletons
with a mean z-score of 0.17 (reference: Dutch population of
newborn children reported by PRN Foundation, 2013). The
birth weight of almost half of the children who were part of a
twin was considered to be low or very low, as was the birth
weight of more than two third of the children who were part of
a triplet. Only one singleton had a very low birth weight. This
child weighed 1490 g and was born by selective cesarean
section at 35 + 2 weeks gestational age, because of hemolysis,
elevated liver enzymes low platelet—syndrome (HELLP) in
the mother.
Perinatal mortality and morbidity
Perinatal mortality was reported in three pregnancies (0.8%).
One boy of a twin died at 23 weeks and 4 days gestational age,
following the miscarriage of his sibling at 16 weeks gestation-
al age. One of a triplet showed growth retardation on ultra-
sound and died in utero at 32 weeks gestational age. A single-
ton was stillborn at 37 weeks gestational age after an uncom-
plicated pregnancy. Chromosomal analysis of the latter
showed a balanced male karyotype and extensive postmortem
examination revealed no dysmorphic features or congenital
malformations and no cause for his intrauterine death (Table
3).
Hospital admission was required in 18.4% of the children.
The most common reasons for admission were prematurity,
(very) low birth weight or a combination of both. Other rea-
sons for admission directly after birth were blood glucose
level monitoring, hyperbilirubinemia, and low body tempera-
ture. One girl was admitted a week after birth because of a
pyelonephritis (Table 3).
Some of the data of the Dutch PGD population are also
presented in Supplementary Table 1, as are the data of other
PGD cohorts that we have found in the literature and the
outcomes of a meta-analysis on IVF-ICSI studies.
Table 1 Couple, treatment, and child characteristics
Mean maternal age (years + SD) 32.3 ± 3.7
Mean paternal age (years + SD) 35.2 ± 4.5
Number of clinical pregnancies 439
Mode of inheritance in PGD pregnancies
Autosomal dominant 172/439 (39.1%)
Chromosomal 121/439 (27.6%)
X-linked 77/439 (17.5%)
Autosomal recessive 65/439 (14.8%)
Mitochondrial 4/439 (0.9%)
Nulliparous 245/439 (55.8%)













Number of blastomeres biopsied per embryo
1 321/649 (49.5%)
2 328/649 (50.5%)











a Two children were lost to follow-up
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Discussion
PGD is nowadays a worldwide applied technique for the pre-
vention of genetic disease in offspring. Data on the safety of
PGD, namely on congenital malformation rate and adverse
perinatal outcome, are mostly reported by one specific PGD
center or based on data deduced from a small study popula-
tion. The main objective of this study was to give an overview
of data from a large PGD population in order to provide in-
formation on the congenital malformation rate, misdiagnosis
rate, birth parameters, perinatal mortality, and adverse perina-
tal outcomes. We report on 364 children and 439 PGD preg-
nancies. This is data of one of the larger PGD populations
published so far.
More girls than boys have been born after PGD treatment,
with a ratio of 1.2 for girls. Sex-selection, followed by the
transfer of a female embryo, is possible for carrier women of
severe X-linked conditions. Corrected for sex-selection in 53
children, a ratio of 1.1 for boys was found, which is in line
with the population-based ratio in favor of boys [20].
The major malformation rate in our group of live born PGD
children was 2.5%. When including pregnancy terminations
due to congenital malformations, this was 3.3%. Other studies
of PGD children reported a comparable major malformation
rate between 1.7 and 4.1% in live born children
(Supplementary Table 1) and conclude this to be equal to the
risk on major malformations for IVF-ICSI children. In a meta-
analysis, Pandey et al. stated that the relative risk for congen-
ital anomalies in IVF-ICSI pregnancies is 1.67 (1.33–2.09)
when compared to natural conceptions and they reported an
increase in absolute risk of 2% (1–2%) [4]. However, the
European Surveillance of Congenital Anomalies reported a
prevalence of 261.45 major and minor birth anomalies per
10,000 births (2.6%) in the period between 2008 and 2012,
which is similar to the prevalence in our PGD cohort [18].
Overall, the risk onmajor malformations in children born after
PGD seems not increased when compared to the general pop-
ulation. Our study shows similar results.
In four cases (1.1%)with congenital malformations, a chro-
mosomal abnormality was detected. All of these cases in-
volved autosomal chromosomes and were not related to the
PGD indication. Of the two trisomy 21 cases, the mothers that
were aged 31 and 34 and the fathers that were 31 and 35 years
old were not known to be subfertile and one father did report
to be a heavy smoker during the intake interview. The mother
of the fetus with trisomy 18 was 34 years old. Influence of
paternal age and smoking habits on aneuploidy is still contro-
versial [21]. Liebaers et al. reported on one case with a chro-
mosomal abnormality, in their PGD cohort [12]. Other studies
do not report on chromosomal aberrations in their PGD co-
hort. Bonduelle et al. reported a de-novo chromosomal anom-
aly rate of 1.6% in ICSI offspring [22]. Results of prenatal
diagnostic tests in a large group of naturally conceived women
Table 2 Congenital malformations, misdiagnosis, and genetic testing in
PGD children and pregnancies
Live born N = 364a
Major malformations 9 (2.5%)
Multiple malformations 4 (1.1%)
Trisomy 21 1











Duodenal web 1 (one of a twin)
Hypospadia 1
Congenital heart disease 2
Minor malformations 5 (1.4%)
Sacral dimple 2
Umbilical hernia 2 (dizygotic twin)
Inguinal hernia 1
Total 14 (3.8%)
Pregnancies N = 439
Still birth 1 (0.2%)
Acardia 1 (one of a triplet)




Genetic testing N (%)
Non-viable fetus/stillbirth 3
8 weeks and 5 days
gestational age
1 (trisomy 16)












3 (one trisomy 18, others normal)
Maternal age 6 (all normal)
Increased risk combined
test












3 (one mosaicism trisomy 9; one
trisomy 21; one normal)
a Two children were lost to follow-up and therefore excluded; b [24];
c Intra uterine fetal death
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aged 35 years and older showed an incidence of chromosomal
abnormalities of 0.9% [23]. Our results seem to be in line with
this; however, the mean age of the mothers in our cohort was
slightly lower (32.3 ± 3.7). More evidence is needed before
any conclusions on the risk of chromosomal abnormalities
can be drawn.
The one misdiagnosis described was probably due to a
technical error. An unbalanced fetal karyotype is 47,XX,+
der(5)t(X;5)(q13;p14)mat. This case has been extensively
reviewed [24]. Prenatal genetic testing to confirm the PGD
diagnosis was offered to all couples, but was performed in
only 10% of the pregnancies. An exact misdiagnosis rate
can therefore not be given. Based on our perinatal data, we
have no indication to expect more misdiagnosis, bearing in
mind that manifestations of late-onset diseases are not yet
expected due to the short follow-up time. The European
Society of Human Reproduction and Embryology PGD con-
sortium reports a misdiagnosis rate of 0.16%, with the anno-
tation that there is a possibility that not all misdiagnosis have
been declared by the PGD centers, and this could be an un-
derestimation [25]. The same consortium evaluated the valid-
ity, robustness, and diagnostic value of PCR-based PGD [26,
27]. These data seem reassuring when assessing the safety of
PGD.
Almost 20% of the children included in this study were
born premature. Less than 15% of the children had a low
birth weight. These were mostly multiples. We calculated a
z-score of + 0.17 for the singletons which indicates a com-
parable birth weight between our PGD children and the
Dutch population. The prematurity rate in the PGD cohorts
of Eldar-Geva et al. (15.5%) and Liebaers et al. (28.9%)
matches with the incidence of low birth weight in their co-
horts, which seems to indicate a correlation [11, 12]. All
other studies on PGD and PGS show an evident increase
in prematurity in multiples when compared to singletons,
as does the risk for low and very low birth weight (see for
a summary Supplementary Table 1). Our study distin-
guished very premature children from premature children
which shows that the very premature children were all part
of a twin. Bay et al. found an increased risk on adverse birth
outcomes in PGD children when compared to children born
after naturally conceived pregnancies. [8] The incidence of
multiples in their PGD cohort was 30%, compared to an
incidence of 3% in naturally conceived children.
Considering the possibly higher perinatal risk for multiples
this strongly supports the current SET policy. Since gesta-
tional age and birth weight in PGD children are comparable
to these parameters in IVF-ICSI children it could be sug-
gested that PGD on itself is not an extra risk factor for ad-
verse perinatal outcome [8, 10, 28].
We report one unexplained stillbirth at 37 weeks gestation-
al age. Liebaers et al. reported the perinatal mortality rate to be
higher in PGD children (4.64%) compared to ICSI children
[12]. However, when they stratified for multiples the increased
risk of perinatal death in PGD and ICSI singletons was com-
parable (1.03%). A meta-analysis by Lamont et al. of cohort
and case-control studies describes population-based data on
3,412,079 women from high income countries, of whom
Table 3 Birth parameters,
perinatal mortality, and hospital
admissions
Total Singletons Twins Triplets
Total 364 263 (72.3%) 88 (24.2%) 13 (3.6%)
Term (mean in weeks) 38.6 39.2 36.3 34.1
Premature (< 37 weeks) 63 (17.3%) 20 (7.6%) 35 (39.8%) 8 (61.5%)
Very premature (< 32 weeks) 8 (2.2%) – 8 (9.1%) –
Birth weighta N = 359 N = 262 N = 84 N = 13
Median in grams 3280 3462 2640 1900
Mean in grams (SD) 3199 (± 699) 3450 (± 533) 2554 (± 610) 2148 (± 696)
Mean z-scoreb 0.17
Low birth weight (< 2500 g) 52 (14.3%) 10 (3.8%) 31 (36.9%) 9 (69.2%)
Very low birth weight (< 1500 g) 9 (2.5%) 1 (0.4%) 8 (9.5%) –
Perinatal mortality 3 (0.7%) 1 (0.3%) 1 (0.3%) 1 (0.3%)
Hospital admission 67 (18.4%) 36 (9.9%) 25 (6.9%) 8 (2.2%)
Low birth weight 28 (7.7%)
< 37 weeks 34 (9.3%)
aData on birth weight were missing of five children
bWeight of the individual child minus the meanweight of children of mothers being nulliparous or multiparous as
well, who have the same gender and ethnical background and were born at the same gestational age within a
reference population, divided by standard deviation (PRN Foundation, 2013). References only available for
singletons
SD, standard deviation
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24,541 (0.7%) had a stillbirth [29]. The perinatal mortality rate
in our cohort is 0.8%. We found no evidence for a potential
increased risk on fetal or neonatal death after PGD.
The incidence of hospital admissions is lower for our PGD
children than previously described in PGD cohorts
(Supplementary Table 1). These admissions were not associ-
ated with the incidence of multiple pregnancies as previously
seen in IVF-ICSI cohorts. Explanations for associations found
in these latter studies were the higher incidence of preterm
birth and low birth weight seen in multiples. There seems to
be a relation between the prematurity rate, birth weight, and
hospital admissions in our PGD cohort since half of the ad-
mitted children were born premature.
This study is one of the first large studies on exclusively
PGD pregnancies and children. Other studies reported mostly
on children born after preimplantation genetic screening
(PGS) and completed their cohort with data on children born
after PGD. Contrary to PGD, PGS is offered to couples with
an IVF-ICSI indication due to infertility or advanced maternal
age and is considered to increase the probability of achieving a
pregnancy by excluding aneuploid embryos [30]. Our pro-
spectively gathered data are rather complete as only two chil-
dren were lost to follow-up. Our results include data on peri-
natal events and also pregnancy terminations before the peri-
natal period, loss of children, and congenital malformations in
pregnancy. Other studies mostly omitted these latter data. This
study population consists of all PGD pregnancies in one coun-
try and is not restricted to one specific PGD center or area.
In this report, the data of the Dutch PGD population
were compared to published PGD cohorts, mainly from
Belgium, and to published data on naturally conceived
pregnancies and children and IVF-ICSI pregnancies and
children. A future study on the Dutch PGD population
with comparison to Dutch IVF-ICSI and naturally con-
ceived children is desirable. Thereby, the children of the
Dutch PGD population were not examined by the research
group which could introduce an underestimation of the
number of, mainly minor, congenital malformations. As
Robins et al. reported that over 40% of congenital
malformations are diagnosed only after 1 month postpar-
tum [31]. A follow-up study of older PGD children com-
pared to IVF-ICSI children and naturally conceived chil-
dren is ongoing.
Overall, the risk on major malformations in PGD chil-
dren seems comparable to children born after IVF-ICSI as
to the risk reported in naturally conceived children. Data
on pregnancy duration, birth weight, perinatal mortality,
and hospital admissions in the Dutch PGD population, es-
pecially in the singletons, appear to be similar to the pub-
lished data on naturally conceived children. In conclusion,
PGD does not seem to attribute to an increased risk on an
adverse perinatal outcome when compared to naturally
conceived children.
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